Insider Selling: AC Immune (NASDAQ:ACIU) CEO Sells $27,900.00 in Stock

AC Immune (NASDAQ:ACIU) CEO Andrea Pfeifer sold 10,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $2.79, for a total transaction of $27,900.00. Following the sale, the chief executive officer directly owned 3,820,288 shares of the company’s stock, valued at approximately $10,658,603.52. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AC Immune Stock Performance

ACIU stock opened at $2.89 on Thursday. The firm has a market cap of $294.12 million, a price-to-earnings ratio of -3.52 and a beta of 1.65. The firm has a 50-day simple moving average of $2.95 and a two-hundred day simple moving average of $3.07. AC Immune has a one year low of $1.60 and a one year high of $4.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $1.40 million during the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. On average, equities analysts forecast that AC Immune will post -0.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on ACIU shares. Jefferies Financial Group reissued a “buy” rating and set a $7.00 price target on shares of AC Immune in a research report on Friday, March 13th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Monday, May 4th. Weiss Ratings lowered shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. Finally, Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.50.

Hedge Funds Weigh In On AC Immune

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership raised its position in shares of AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after purchasing an additional 30,035 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of AC Immune by 82.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after purchasing an additional 172,796 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of AC Immune in the 4th quarter valued at approximately $586,000. Finally, Sei Investments Co. purchased a new position in shares of AC Immune in the 2nd quarter valued at approximately $51,000. 51.36% of the stock is owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.